1. Home
  2. HLN vs ARGX Comparison

HLN vs ARGX Comparison

Compare HLN & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Haleon plc (Each representing two)

HLN

Haleon plc (Each representing two)

HOLD

Current Price

$9.88

Market Cap

41.7B

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$850.23

Market Cap

51.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HLN
ARGX
Founded
2022
2008
Country
United Kingdom
Netherlands
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.7B
51.1B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
HLN
ARGX
Price
$9.88
$850.23
Analyst Decision
Hold
Strong Buy
Analyst Count
1
19
Target Price
N/A
$971.89
AVG Volume (30 Days)
10.3M
340.7K
Earning Date
07-31-2025
10-30-2025
Dividend Yield
1.85%
N/A
EPS Growth
41.64
N/A
EPS
0.23
23.27
Revenue
$15,096,588,575.00
$3,683,281,000.00
Revenue This Year
$1.51
$91.22
Revenue Next Year
$4.67
$36.36
P/E Ratio
$42.93
$34.93
Revenue Growth
N/A
92.98
52 Week Low
$8.71
$510.06
52 Week High
$11.42
$934.62

Technical Indicators

Market Signals
Indicator
HLN
ARGX
Relative Strength Index (RSI) 60.14 37.51
Support Level $9.68 $827.52
Resistance Level $9.65 $878.19
Average True Range (ATR) 0.15 17.90
MACD 0.02 -9.73
Stochastic Oscillator 92.06 18.94

Price Performance

Historical Comparison
HLN
ARGX

About HLN Haleon plc (Each representing two)

Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: